Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05827679
Other study ID # RNI 2022 COLNE
Secondary ID 2022-A02779-34
Status Completed
Phase
First received
Last updated
Start date March 15, 2023
Est. completion date September 1, 2023

Study information

Verified date April 2023
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Every year in France, 60,000 children are born prematurely (before 37 weeks of amenorrhea), and present an immaturity of their various systems, in particular the digestive system. This can result in feeding intolerance, which is expressed by abdominal distension, regurgitation or vomiting, irregular transit and abdominal discomfort. This feeding intolerance influences the length of hospitalization and can lead to necrotising enterocolitis, a major complication. In the Neonatal Intensive Care Units of Clermont-Ferrand hospital center, abdominal massages have been performed by physiotherapists for several years in order to improve the condition of the digestive system. However, the indication for abdominal massage is very dependent on the caregivers in charge of the newborn and the evaluation of the abdominal condition remains subjective with a great variability between examiners. Thus, some newborns will receive massage multiple times a day while others will not. Developmental care is essential for these premature infants, especially to avoid over-stimulation. It is important not to add care, such as massage, if it is not needed. It is therefore essential to properly assess the digestive status of premature babies in order to determine whether they have feeding intolerance and whether they require treatment with abdominal massage. To date, the investigators have not found measurable criteria or existing scales that can describe the digestive status of newborns. The main objective of the study is therefore to create and validate a clinical assessment scale for the abdominal status of preterm infants.


Description:

This is an observational study with longitudinal follow-up regarding the validation of a scale that the investigators have created. Inclusions will be made when the patient arrives at the Clermont-Ferrand hospital center in the neonatal intensive care units. The patients will be evaluated daily from the 3rd day of life by the nurse, the physiotherapist and the resident of the service. The evaluation will be carried out at least 8 times over 21 days. If an abdominal massage is performed, an assessment of the abdominal condition by the scale will be necessary before and after each massage by the physiotherapist. Each assessment (by physio, nurse and resident) will be blinded and within a maximum time window of 30 minutes. The first evaluator clears the patient's abdomen (clothing and diaper removed) and then performs the assessment of the abdomen blindly. A description has been written so that each evaluator can use the ECAP scale under the same conditions and with well-detailed judgment criteria in order to have an evaluation that is as reliable as possible. The time taken to assess the premature baby's abdomen by the ECAP scale is less than 3 minutes. The evaluator fills out the ECAP assessment table, blindly. Within the next 30 minutes (the patient's abdominal condition is considered stable during this time), the second and third assessors have to do the same. These assessments are stored together with each patient's clinical data collection, and then analyzed by statisticians.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date September 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers
Gender All
Age group 3 Days to 60 Days
Eligibility Inclusion Criteria: - newborns, born prematurely (before 37 weeks of amenorrhea) - at least 3 days of life - hospitalized in the neonatal intensive care units - whose holders of parental authority are able to give free and informed consent to participate in this study Exclusion Criteria: - Newborns with congenital pathology such as malformation, genetic or chromosomal abnormality. - Newborns whose holders of parental authority are protected by law (under guardianship) or under the age of 18. - Rejection of participation by parents

Study Design


Locations

Country Name City State
France CHU clermont-ferrand Clermont-ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Abdominal assessment scale for Preterm infant (ECAP scale) score between 0 and 20 up to 18 months
Secondary Indication for abdominal massage on ECAP scale score on the Clinical Abdominal assessment scale for Preterm infants, between 0 and 20 (higher scores meaning worse outcome) up to 18 months
Secondary ECAP scale validity term of birth population up to 18 months
Secondary impact of massage on ECAP scale variation of the score of Clinical Abdominal assessment scale for Preterm infants, between 0 and 20 (higher scores meaning worse outcome) up to 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT05066139 - Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G) N/A
Recruiting NCT04475952 - Early Diagnosis of Upper Digestive Tract Disease
Completed NCT05064163 - SROI Project on the Surgical Waiting List Management System
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT03723447 - Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) Phase 4
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT03008460 - Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy Phase 3
Active, not recruiting NCT05253859 - CFTR Modulators and Gastrointestinal Complications
Not yet recruiting NCT05636657 - Comparative Study of Intestinal Color Ultrasound and Capsule Endoscopy in Monitoring Crohn's Disease
Completed NCT05160077 - Optoacoustic Characterization of Postprandial Intestinal Blood Flow N/A
Recruiting NCT05401058 - Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery N/A
Completed NCT06283732 - A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience. N/A
Not yet recruiting NCT06271538 - Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome Phase 4
Terminated NCT03594331 - Gastric Gluten-Degradation Activity of PvP001 Phase 1
Not yet recruiting NCT05405842 - Transauricular Vagal Nerve Stimulation; Functional Dyspepsia and Gastroparesis N/A
Recruiting NCT06351202 - Impact Assessment of Abdominal Massage on Feeding Tolerance of Preterms N/A
Completed NCT02785783 - Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection N/A
Completed NCT00072943 - A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2